ANIX
Anixa Biosciences Inc
Key Financials
Revenue
$210000
0.0%
Net Income
$-10927000
↑ 13.0%
Operating Income
$-11701000
↑ 15.4%
EPS (Diluted)
$-0.34
↑ 12.8%
Total Liabilities
$2.1M
↓ 21.2%
Total Assets
$16.1M
↓ 25.5%
Long-term Debt
$370181.00
0.0%
Cash & Equivalents
$1.2M
↓ 2.1%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 6/17/2026 | View on SEC |
| 4 | 6/16/2026 | View on SEC |
| 10-Q | 6/10/2026 | View on SEC |
| 8-K | 3/11/2026 | View on SEC |
| 10-Q | 3/9/2026 | View on SEC |
| 8-K | 2/9/2026 | View on SEC |
| 4 | 1/29/2026 | View on SEC |
| DEF 14A | 1/28/2026 | View on SEC |
| S-8 | 1/12/2026 | View on SEC |
| 10-K | 1/12/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ANIX |
| Company Name | Anixa Biosciences Inc |
| CIK | 715446 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1031 |
| State of Incorporation | DE |
| Phone | 408-708-9808 |